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ABSTRACT
Our previous studies in mice showed that the nonmyeloablative conditioning regimen of fractionated irradi-
ation of the lymphoid tissues (total lymphoid irradiation; TLI) and depletive anti-T–cell antibodies (anti-
thymocyte serum) markedly increased the percentage of regulatory DX5 and natural killer 1.1 T cells in the
mouse spleen, and prevented acute lethal graft-versus-host disease (GVHD) in BALB/c mice (H-2d) following
the transplantation of bone marrow (BM) and peripheral blood mononuclear cells (PBMC) from C57BL/6
(H-2b) donors. The object of the current study was to determine whether the TLI and anti-thymocyte serum
regimen protected natural killer T-cell deficient CD1/ BALB/c mice against GVHD after BM and PBMC
transplantation from C57BL/6 donors, and whether a similar conditioning regimen of TLI and anti-thymocyte
globulin (ATG) can prevent GVHD in Lewis rat (RT1l) hosts after BM and PBMC transplantation from ACI
rat (RT1a) donors. The experimental results in mice showed that, although wild-type BALB/c hosts are
protected in association with a marked increase in CD1- reactive T cells expressing the invariant TCR
identified with a CD1 tetramer reagent; CD1/ BALB/c hosts are not. Studies of chimeric donor cells in mice
protected from GVHD showed donor T-cell polarization to a Th2 cytokine pattern. Results in rats showed that
approximately 1000 fold more donor PBMC cells were required to induce a similar incidence of lethal GVHD
in TLI and ATG conditioned hosts as compared with hosts conditioned with single-dose total-body irradiation
or total-body irradiation and ATG. Surviving TLI and ATG conditioned rat hosts were complete chimeras. In
conclusion, the TLI and ATG/anti-thymocyte serum conditioning regimen protects against GVHD in rats and
mice, and regulatory natural killer T cells are required for protection.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Nonmyeloablative host conditioning regimens
have decreased the early toxicity associated with allo-
geneic bone marrow (BM) and blood stem cell trans-
plantation in humans [1-4]. However, graft-versus-
host disease (GVHD) continues to be an important
problem, and 10% to 40% of hosts develop at least
grade II GVHD even with reduced toxicity regimens
[1-4]. Several approaches have been reported to ame-
liorate GVHD including manipulation or elimination
of donor T cells [5-7], and manipulation of the host to
eliminate antigen presenting cell targets of GVHD
[8].
Our previous studies have shown that GVHD can
also be prevented by manipulating the host to alter the
balance of residual T cells to favor the presence of
regulatory T cells (Treg) cells [9]. Two types of mouse
Treg cells have been reported to suppress GVHD,
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natural killer (NK) T cells, and CD4CD25 T cells
[9-12]. Whereas the CD4CD25 T cells of donor
origin can protect against GVHD induced by conven-
tional donor T cells, NK T cells of either host or
donor-type are protective [9,10,13]. The latter Treg
cells recognize CD1, a nonpolymorphic MHC class
I-like molecule expressed by both host and donor-type
cells regardless of the mouse strains used [14].
Conditioning mice with a combination of total
lymphoid irradiation (TLI) and depletive anti-T–cell
antibodies (anti-thymocyte serum; ATS) alters the
balance of residual T cells such that the percentage of
NK T cells among all T cells increases from about 1%
to 2% before treatment to more than 90% after 17
doses of TLI (240 cGy each) and 3 doses of ATS given
over a 3-week period [9]. The conditioned mice accept
combined peripheral blood mononuclear cell (PBMC)
and bone marrow transplants (BMT) from MHC-
mismatched donors and become stable mixed chime-
ras [9]. The hosts do not develop acute lethal GVHD,
as do all hosts conditioned with TBI or TBI and ATS
that are given the same donor cell transplants [9].
Protection against GVHD can be transferred by T
cells from the spleen of TLI-treated mice [9].
In the current study, we determined whether the
TLI and depletive anti-T–cell antibody conditioning
regimen could protect Lewis rats from GVHD after
transplantation of MHC-mismatched PBMC and BM
cells from ACI donors. Our previous studies showed
that rats require fewer doses of TLI than mice (10 v 17
doses of 240cGy each) for engraftment of MHC-
mismatched BMTs [15], and the TLI ﬁelds in rats are
more similar to that used in humans. The results
showed that the TLI regimen (10  24 cGy) used in
rats is markedly protective as compared with TBI, and
approximately 1000 fold more donor T cells are re-
quired to induce lethal GVHD using the former ver-
sus the latter conditioning regimen. In addition, we
determined whether the presence of NK T cells in
host mice are required for protection against GVHD
after TLI conditioning by comparing NK T-cell de-
ﬁcient CD1/ hosts and wild-type hosts. We found




Adult male Lewis (RT1l) and ACI (RT1a) rats
weighing 280 to 299 g and 181 to 195 g, respectively,
were purchased from Harlan Sprague Dawley, Inc
(Walkersville, MD). Male C57BL/6 (H-2b) and
BALB/c (H-2d) wild-type mice 8 to 10 weeks old were
purchased from the Department of Compara-
tive Medicine, Stanford University (Stanford, CA).
CD1/ BALB/c mice were kindly provided by Drs
M.A. Exley and S.P. Balk (Harvard University, Bos-
ton, MA), and were backcrossed more than 10 gener-
ations on the BALB/c background.
Irradation
Total lymphoid irradiation was delivered to the
abdomen, lymph nodes, thymus, and spleen with
shielding of the skull, lungs, limbs, pelvis, and tail as
described previously. Total lymphoid irradiation in
Lewis recipients was started on day 14 before BMT
and 10 doses of 240 cGy were administered as 5 doses
per week. Total lymphoid irradiation in BALB/c mice
was started on day 24 before transplantation, and 17
doses of 240 cGy each were administered. Total body
irradiation was delivered to control Lewis recipients
(1050 cGy) or BALB/c recipients (800 cGy) 24 hours
before cell infusions. The irradiation was performed
with a Philips x-ray unit (200 kV, 10 mA; Philips
Electronic Instruments, Inc, Rahway, NJ) at a rate of
84 cGy/min with a 0.5 mm Cu ﬁlter.
Rabbit Anti-Thymocyte Globulin or Serum
New Zealand rabbit ATG was prepared as de-
scribed previously [15]. Rabbit ATS was purchased
from ACCURATE Laboratories (New York, NY).
Lewis rats were injected intraperitoneally with 20
mg/kg ATG on days 14 and 12, and 10 mg/kg on
days 10, 8, and 6. BALB/c mice were injected
intraperitoneally with 0.05 mL ATS in 0.5 mL saline
on days 12, 10, and 8.
Cell Preparation
Peripheral blood mononuclear cells were isolated
on density gradients (Lympholyte-Rat or Lym-
pholyte-M Cedarlane Laboratories, Ontario, Canada),
and washed twice in ice-cold RPMI-1640 (Gibco,
BRL Laboratories, Grand Island, NY). Femoral and
tibial bones taken from donor ACI rats or C57BL/6
mice were rinsed, and residual muscle on the bones
were carefully removed. Bone marrow cells were pre-
pared by ﬂushing the bones with RPMI-1640, and the
cell suspension was ﬁltered through nylon mesh to
remove aggregates, and washed once before transfu-
sion.
Flow Cytometry
Blood samples for rat and mouse chimerism anal-
yses were hemolyzed with ammonium chloride potas-
sium carbonate to remove red cells. The white cell
pellets were washed twice with 0.05% sodium azide
staining buffer, and incubated on ice for 15 minutes
with saturation concentrations of monoclonal anti-
body mixtures as described previously [9,15]. Biotin-
ylated anti-RT1Aa,b (C3), APC conjugated anti-CD3
(G41.8) from Pharmingen, San Diego, CA and ﬂuo-
rescein isothiocyanate conjugated anti-granulocyte
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and macrophage (R2-1A6a), and phycoerythrin con-
jugated anti-Pan–B (RLN-9D3) monoclonal antibod-
ies from Caltag (Burlingame, CA) were used for rat
chimerism analysis. Biotinylated anti-Gr–1 (RB6-
8C5) and anti-Mac–1(M1/70.15), and APC conju-
gated anti-B220 (RA3-6B2) from Caltag, as well as
ﬂuorescein isothiocyanate conjugated anti-H–2Kb
(AF6-88.5) and phycoerythrin conjugated anti-Thy1.2
(53-2.1) monoclonal antibodies from Pharmingen
were used for mouse chimerism analyses. After incu-
bation, cells were washed twice and followed by
streptavidin-Texas Red (Caltag) staining on ice. Back-
ground staining for donor-type cells in normal control
Lewis rats and BALB/c mice was 0.5%. For detec-
tion of CD1-reactive NK T cells in the spleen of
BALB/c mice, splenocytes were incubated with a mix-
ture of phycoerythrin conjugated CD1 tetramers
loaded with  galactosyl ceramide [16] and APC con-
jugated anti-TCR (H57-597) from Pharmingen.
All mouse cells were incubated with CD16/32 (2.4G2)
from Pharmingen to block the FcR- II/III receptors,
and propidium iodide was added to exclude dead cells.
Chimerism analysis used a lymphoid gate set by for-
ward and orthogonal light scatter [9,15].
Cytokine Assays
Details of in vitro stimulation of sorted cell pop-
ulations with phorbol myristate acetate and ionomycin
and analysis of IL-4 and IFN- in the 48-hour super-
natants by enzyme-linked immunosorbent assay
(ELISA) assays are described elsewhere [9].
Histopathology of Liver, Skin, and Intestines
Tissues were ﬁxed in formalin, embedded in par-
afﬁn blocks, and sections were stained with hematox-
ylin and eosin.
Statistical Analysis
Different groups of hosts given BMTs were com-
pared for statistical differences in survival using the
log rank test. Difference in mean levels of in vitro
cytokine secretion were analyzed using the 2-tailed
student t test of independent means.
RESULTS
Protection against Graft-versus-Host Disease in
MHC-Mismatched Rats
Adult Lewis (RT1l) rats given a single dose of TBI
(1050 cGy) and an intravenous injection of BM cells
(100  106) from MHC-mismatched ACI (RT1a) do-
nors survived at least 100 days without clinical signs of
GVHD (Figure 1A). However, addition of 25  106
ACI PBMC to the BM cell infusion resulted in the
death of all hosts by 20 days which was associated with
typical features of GVHD including diarrhea, weight
loss, hunched back, and hair loss (Figure 1A) (P .01;
log rank test). Control hosts given irradiation without
cells all died by day 10 (Figure 1A).
Lewis hosts given TLI in 10 doses of 240 cGy each
(total dose, 2400 cGy) targeted to the lymph nodes,
spleen, and thymus with shielding of the BM, lungs,
and other radiosensitive tissues during a 2-week pe-
riod before the infusion of 100 106 ACI BM cells all
survived for at least 100 days without clinical signs of
GVHD (Figure 1B). However, injection of 25  106
PBMC together with the marrow cells resulted in
uniform death by 24 days (Figure 1B) (P .001). The
radiation regimen was nonmyeloablative, and all irra-
diated hosts survived at least 100 days without a cell
infusion (Figure 1B). In contrast, when Lewis hosts
were given TLI and 5 intraperitoneal injections of
rabbit ATG (a potent T-cell depletive reagent) during
the ﬁrst week of irradiation (days14,12,10,8,
6), the subsequent injection of ACI BM and PBMC
Figure 1. Survival of Lewis rat hosts given BMTs from ACI rat
donors. A, Hosts were given a single dose of 1050 cGy TBI without
a cell infusion or with an intravenous injection of 100  106 ACI
BM cells alone, ACI BM cells with 25  106ACI PBMC, or TBI
combined with rabbit ATG and an injection of 100  106ACI BM
cells and 25 106 PBMC (n 6 in all groups). B, Hosts were given
2400 cGy TLI without a cell infusion, TLI with BM cells, or TLI
with 100  106 BM cells and 25  106 PBMC (n  6 in all groups).
C, Hosts were given TLI and ATG without a cell infusion, TLI and
ATG with 100  106 BM cells, or TLI and ATG with 100  106
BM cells and 25  106 PBMC (n  5 in all groups). Data from 2
replicate experiments were combined and groups were set up con-
currently for each experiment.
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failed to induce uniform acute lethal GVHD, and 4 of
5 hosts survived at least 100 days (Figure 1C). Intra-
peritoneal injections of ATG on days 14, 12, 10,
8, and 6 before TBI instead of TLI failed to
protect Lewis hosts from GVHD induced by ACI BM
and blood mononuclear cells, and all died by day 18
(Figure 1A). Thus, the TLI and ATG regimen re-
sulted in markedly improved survival as compared to
the TBI and ATG regimen (P  .001).
To determine the magnitude of protection against
GVHD afforded by the TLI and ATG regimen as
compared with conventional single-dose TBI, groups
of Lewis hosts were given either of the 2 preparatory
regimens and a subsequent infusion of a constant
number (100  106) of ACI marrow cells and graded
numbers of PBMC. In groups given TBI, injection of
as few as 0.1 106 PBMC resulted in the death of two
thirds of hosts within 60 days, and 0.8  106 cells
induced uniform death by 42 days (P  .01 as com-
pared with marrow cells alone) (Figure 2A). Injection
of 12.5  106cells killed all hosts by 20 days. In
contrast, injection of marrow and 6.25  106 PBMC
into groups prepared with TLI and ATG resulted in
uniform survival of hosts for at least 100 days (P  .01
as compared with TBI with 0.8  106 PBMC)(Figure
2B). Injection of marrow and 100  106 PBMC in-
duced death in 60% of hosts by 60 days (Figure 2B).
Thus, survival curves were similar when the dose of
PBMC was about 1000-fold greater (100  106 versus
0.1 106) using TLI and ATG as compared with TBI
(P 	 .05).
Histopathologic analysis of the tissues of 6 host
rats that received the protective preparatory regimen
and a combined infusion of BM cells and PBMC were
examined when the surviving hosts were sacriﬁced
within 1 week after the 100-day observation period. In
all cases, microscopic analysis of the liver, small and
large intestines, and skin was performed using hema-
toxylin and eosin staining to look for evidence of
GVHD. Positive control tissues were those from 4
Lewis rat hosts that had survived at least 40 days after
treatment with TBI, 100  106 BM cells, and low
doses of PBMC (Figures 3A and B). Typical micro-
scopic changes of GVHD in the skin included epider-
mal hyperplasia, a dermal inﬂammatory inﬁltrate, sub-
epidermal blistering, and necrotic keratinocytes
(Figure 3A). In the large intestine, changes included
crypt apoptosis and inﬂammation and atrophy of mu-
cin containing glandular cells (Figure 3B). These
changes were not observed after 100 days in 6 of 6
Lewis rat hosts given the protective regimen as shown
in representative tissue sections from a host in Figures
3C and D. The epidermis was 1 to 2 cells thick (Figure
3C) and plump mucin-containing cells lined the in-
testinal crypts (Figure 3D). Additional hosts given the
TLI and ATG regimen and BM cells with PBMC
were sacriﬁced at day 40. These hosts showed mild
crypt inﬂammation in the colon, and a mild dermal
inﬂammatory inﬁltrate in the skin despite the lack of
obvious macroscopic skin lesions or diarrhea (data not
shown). Thus, hosts given the protective regimen had
evidence of transient mild microscopic lesions of
GVHD that resolved by 100 days.
Chimerism in Protected Hosts
The percentage of ACI donor-type cells in the
peripheral blood of surviving Lewis hosts injected
with BM cells with or without PBMC was determined
at 100 days by immunoﬂuorescent staining for the
donor-type (RT1Aa,b) marker. Lewis hosts prepared
with TLI and ATG and injected with only donor
marrow cells developed mixed chimerism (mean 43%
donor-type cells; Table 1). All Lewis hosts prepared
with TBI and injected with only donor marrow cells
developed complete chimerism (Table 1). Lewis hosts
treated with TLI, ATG, and an injection of donor BM
and 25 106 PBMC showed complete chimerism also
(Table 1). Representative stainings of nucleated blood
cells from the 3 groups of chimeras for the RT1Aa,b
marker versus T cell, B cell, granulocyte and macro-
phage markers, and subsequent 2-color ﬂow cytomet-
ric analyses are shown in Figure 4. Complete chimer-
ism was observed in all lineages in hosts given TLI,
ATG, BM cells, and PBMC (Figure 4C), and mixed
Figure 2. Survival of Lewis rat hosts given BMT from ACI donors.
A, Hosts were given TBI and100  106 BM cells without PBMC or
with graded doses of PBMC (n  5, 6 in all groups). B, Hosts were
given TLI, ATG, and 100  106 BM cells with graded doses of
PBMC (n  5 for all groups). Data from 2 replicate experiments
were combined. Experiments in Figures 1 and 2 were performed in
the same time interval.
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chimerism was observed amongst T cells and B cells
when marrow cells were given alone (Figure 4A).
Protection against GVHD in Mice is Lost in
CD1/ Hosts
Our previous studies showed that BALB/c (H-2d)
mice conditioned with TLI (17 doses of 240 cGy each;
total dose of 4080 cGy) and 6 doses of ATS were
protected against GVHD after the combined trans-
plantation of 3  106 C57BL/6 (H-2b) donor BM cell
and 0.5  106 donor PBMC [9]. Protection could be
transferred to TBI-conditional hosts with enriched
populations of splenic NK T cells [9]. To determine
whether protection against GVHD after TLI and
ATS conditioning was dependent on the presence of
host NK T cells, we compared the ability of BM and
PBMC mixtures from C57BL/6 donors to induce
GVHD in either wild-type or CD1/ BALB/c hosts.
The latter hosts are deﬁcient in CD1-reactive NK T
cells because of the lack of positive selection by CD1-
expressing cells in the thymus [14]. The percentage of
CD1-reactive NK T cells among all gated TCR
T cells in the spleen of BALB/c mice increased from
2.5% before TLI and ATS treatment to 58.5% after
treatment in wild-type mice, as judged by staining
with CD1d tetramers loaded with  galactosyl cer-
amide. The latter reagent stains only NK T cells
expressing the invariant V14 TCR [16]. However,
Figure 3. Histopathologic examination of Lewis rat hosts given BMT from ACI donors. A, Microscopic section ( 400) of skin from a Lewis
rat host given TBI, 100  106 BM cells and 0.1  106 PBMC. Skin samples were harvested 40 days after BMT. Arrow shows hyperplastic
epidermis, arrow heads show necrotic keratinocytes, and asterisk shows subdermal blister. B, Microscopic section of large intestine of host in
part A. Asterisk shows lymphocyte inﬁltrate surrounding crypts; arrow indicates lymphocyte inﬁltration into crypt. Plump mucin-containing
glandular cells are rare. C, Microscopic section of skin 100 days after BMT from host given TLI, ATG, 100  106 BM cells, and 6.25  106
PBMC. Epidermis is 1 to 3 cells thick, and no dermal inﬁltrate is seen. D, Microscopic section of large intestine from host in part C. Plump
mucin-containing glandular cells are abundant, and no lymphocytic inﬁltrate is observed.
Table 1. Chimerism in Lewis Hosts 100 Days after ACI Bone Marrow Transplantation
Host Treatment Infused Donor Cells % Donor Cells in Blood Mean  SE
TBI 100  106 BM >99  6 >99
TLI  ATG 100  106 BM 1, 87, 4, 67, 82, 18 43  40
TLI  ATG 100  106 BM25  106 PBMC >99  4 >99
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this considerable increase was not observed in
CD1/ BALB/c mice after treatment, and only 3.8%
of tetramer cells were observed (Figure 5A).
Figure 5B shows that wild-type BALB/c hosts
given 800 cGy TBI and a mixture of 3 106 C57BL/6
BM cells and 0.5  106 C57BL/6 PBMC all died by
day 32. These hosts had typical clinical signs of
GVHD. Addition of 3 doses of ATS on days 12,
10, and8 failed to protect the hosts and all died by
day 52 (Figure 5B). In contrast, 5 out of 6 wild-type
BALB/c hosts given 17 doses of TLI and 3 doses of
ATS followed by infusion of the same mixture of
C57BL/6 BM and PBMC survived for at least 100
days (Figure 5B) (P  .01 TBI versus TLI and ATG).
When CD1/ BALB/c hosts were given the same
TLI and ATS conditioning regimen followed by the
infusion of C57BL/6 BM cells and PBMC, the hosts
developed clinical signs of GVHD, and all died by day
53. There was a signiﬁcant difference (P  .01) in
survival between the wild-type and CD1/ groups of
hosts. Wild-type BALB/c hosts that were conditioned
with TLI and ATS, and that survived for at least 100
days were all mixed chimeras amongst T cells, B cells,
and granulocytes and monocytes in the peripheral
blood (data not shown).
Protected BALB/c Chimeras Show a Th2 Bias
In vivo activation of NK T cells has been reported
to induce a Th2 bias among conventional T cells that
protects mice against autoimmune diabetes and en-
cephalomyelitis [17-20]. In addition, Th2 polarized
donor T cells are weak inducers of GVHD as com-
pared with Th1-polarized donor T cells [21,22]. Ac-
cordingly, we assayed the cytokine secretion pattern of
both host and donor T cells in mixed chimeras that
had been protected by the TLI and ATS conditioning
regimen. Wild-type BALB/c hosts that survived at
least 100 days after conditioning with TLI and ATS
and transplantation of a mixture of C57BL/6 BM cells
and PBMC were sacriﬁced and spleen cells were har-
vested. The latter cells were stained with anti-
TCR, anti-H–2Kb, and anti-H–2Kd monoclonal
antibodies. Donor T cells (TCRH-2Kb) and
host T cells (TCR H-2Kd) were sorted using
2-color ﬂow cytometry as shown in Figure 6.
TCR T cells accounted for 24.6% of PBMC, and
sorted donor T cells represented 90% of the gated
TCR cells, and sorted host T cells represented
8%. Equal numbers (0.2  106) of the host and donor
sorted T cells were stimulated in vitro with calcium
ionophore and phorbol myristate acetate, and super-
natants were collected at 48 hours. Control-sorted
splenic T cells from untreated C57BL/6 mice were
stimulated using the same procedures, and superna-
tants were harvested at 48 hours. All supernatants
were assayed for the concentration of IFN- and IL-4
as shown in Figure 6. Whereas, the control C57BL/6
splenic T cells showed a Th1 biased pattern with the
concentration of IFN- at least 10 fold higher than
the concentration of IL-4. The sorted chimeric T cells
Figure 4. Chimerism in Lewis hosts given BMT from ACI donors: Two-color ﬂow cytometric analysis of PBMC from a Lewis host given
either TBI and 100  106 ACI BM cells or TLI, ATG, and 100  106 ACI BM cells with or without 25  106 ACI PBMC. Host cells were
obtained at 100 days, and stained for CD3, pan B, or granulocyte and macrophage markers, and versus RT1A (a,b) (donor type) markers. Boxes
on left enclose host cells, and boxes on right enclose donor cells. Percentages in each box are shown.
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from both donor and host showed a marked increase
in the mean concentration of IL-4 as compared with
that of untreated C57BL/6 and BALB/c mice (P .05
and P  .01 respectively; student t test). There was a
signiﬁcant decrease in the concentration of IFN- as
compared with untreated C57BL/6 mice (P  .01)
such that the ratio of IFN-:IL-4 was reduced to less
than 2 fold (Figure 6). Differences in the IFN- con-
centrations were not signiﬁcant as compared with un-
treated BALB/c mice (P 	 .05).
DISCUSSION
In the current study, we determined whether the
TLI and ATS regimen that was successful in prevent-
ing GVHD in BALB/c mice could be used to protect
Lewis rat hosts from GVHD after combined BM and
PBMC transplantation from MHC-mismatched ACI
donors. Some modiﬁcations of the regimen were
made such that the number of TLI treatments of 240
cGy each was reduced from 17 in the mouse studies to
10 treatments (total dose 2400 cGy) in the rat studies,
and 5 doses of ATG were used in the latter study
instead of 3 doses of ATS used in the former.
As in the mouse studies, the combined TLI and
ATG conditioning regimen protected the Lewis hosts
from acute lethal GVHD observed in TBI-condi-
tioned hosts given a combined inoculum of 100  106
ACI BM and 25  106 ACI PBMC. The addition of
ATG to the TBI conditioning regimen failed to im-
prove the rapid early mortality from GVHD. In fur-
ther studies, TBI- and TLI/ATG-conditioned hosts
were given a constant inoculum of 100 106 ACI BM
cells, and graded doses of ACI PBMC to determine
the number of PBMC required to induce lethal
GVHD in about 50% of both types of hosts. Whereas
0.1  106 donor PBMC induced death in about 60%
of TBI-conditioned hosts by 100 days, the dose of
PBMC required to induce similar mortality in TLI/
ATG-conditioned hosts was 1000 fold higher (100 
106 PBMC).
Lewis hosts conditioned with TLI and ATG and
given ACI 100  106 BM and 25  106 PBMC were
complete chimeras in all cell types in the peripheral
blood (T cells, B cells, monocytes, and granulocytes)
when assayed more than 100 days after transplanta-
tion. As expected from the results of previous studies
[9], host conditioned with TLI and ATG that were
given only ACI BM cells were stable mixed chimeras
at the same time point. Thus, the PBMC facilitated
the transition from mixed to complete chimerism de-
spite the lack of GVHD. This transition has been
reported previously in murine studies in which stable
mixed chimeras given donor lymphocyte infusions be-
came complete chimeras without the development of
clinical GVHD [23].
Histopathologic analysis of Lewis host chimeras
conditioned with TLI and ATG and given combined
ACI BM and PBMC transplants showed no evidence
of microscopic tissue injury in the colon and skin more
Figure 5. Wild-type and NK T-cell deﬁcient CD1/ BALB/c
hosts compared for splenic T cell subsets and for survival after BMT
from C57 BL/6 donors. A, Wild-type or CD1/ BALB/c mice
were given TLI and 3 injections of ATS or no treatment. Immedi-
ately after TLI/ATS conditioning, spleen cells were stained with
anti-TCR monoclonal antibodies versus CD1 tetramers loaded
with  galactosyl ceramide. Panels show tetramer versus TCR
staining of gated TCR T cells. Boxes enclose TCR tet-
ramer cells. Background staining of TCR cells was approxi-
mately 1.5%. B, Control wild-type BALB/c hosts were conditioned
with either TBI (800 cGy) alone or TBI and 3 injections of ATS
(days12,8,6). Experimental wild-type or CD1/ hosts were
conditioned with TLI (17 doses of 240 cGy each) and ATS (days
12, 8, 6). All hosts were given 3  106 C57BL/6 BM cells and
0.5  106C57BL/6 PBMC within 24 hours after the completion of
TLI or TBI. Survival is shown for 6 to 10 hosts in each group.
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than 100 days after transplantation. In contrast, Lewis
hosts conditioned with TBI showed the typical
GVHD-associated changes of crypt cell death and
inﬂammatory cell inﬁltration in the colon and epider-
mal hyperplasia and dermal inﬁltrates in the skin.
To study the role of regulatory NK T cells in the
protection against GVHD afforded by the TLI-based
conditioning regimen, additional studies were per-
formed using NK T-cell deﬁcient CD1/ BALB/c
mice and wild-type BALB/c mice as hosts because
such gene-deﬁcient rats are not available. The TLI
and ATS regimen markedly increased the percentage
of CD1-reactive T cells among all T cells as judged by
staining with CD1 tetramers that bind speciﬁcally to
the invariant V14 TCR expressed by NKT cells [16].
This increase was not observed in CD1/ BALB/c
mice. As in the rat studies, wild-type BALB/c mice
conditioned with TBI or TBI and ATS developed
lethal GVHD after the transplantation of a mixture of
MHC-mismatched PBMC and BM cells. Although
the TLI and ATS conditioning regimen protected
almost all wild-type hosts from severe GVHD and
death during the 100-day observation period, the
same conditioning regimen failed to protect the
BALB/c CD1/ hosts, and all succumbed by about
50 days. This result is consistent with the loss of
protection against GVHD in TLI-conditioned hosts
that were treated with anti-asialo–GM1 antibodies
[24]. In vivo administration of the latter antibodies to
TLI-treated hosts has been shown to deplete NK T
cells [9]. Taken together, the failure of protection of
the TLI conditioning regimen in NK T-cell deﬁcient
hosts, and the ability of enriched populations of
splenic NK T cells to transfer protection to TBI-
conditioned hosts [9], shows that the NK T cells play
a critical role in suppressing GVHD. T cells found in
the spleen of mice given TLI that are capable of
suppressing GVHD were identiﬁed previously as
“natural suppressor” cells [25].
Activation of NK T cells in vivo has been shown to
ameliorate autoimmune diabetes and experimental al-
lergic encephalomyelitis by polarizing conventional
non-NK T cells from a Th1 to a Th2 type of cytokine
secretion pattern [17-20]. We hypothesized that the
suppressive activity of host NK T cells may be because
of the prolonged polarization of donor conventional T
cells toward a Th2 cytokine pattern as reported in the
autoimmune disease models [17-20]. Polarization to-
ward a Th2 pattern in hosts conditioned with TLI has
been previously reported in donor T cells after BMT
[26]. In addition, Th2-polarized donor T cells are
considerably weaker than Th1-polarized donor T cells
in inducing severe GVHD [21-22]. Accordingly, we
sorted both host and donor T cells from the spleen of
chimeric BALB/c mice conditioned with TLI and
ATS more than 100 days after the transplantation of
the donor PBMC and BM cells. The sorted cell pop-
ulations were stimulated in vitro with calcium iono-
phore and phorbol myristate acetate, and both showed
a Th2 biased cytokine secretion pattern. There were
higher levels of IL-4 and lower levels of IFN- as
compared with that observed with sorted T cells from
the untreated donor spleen.
In conclusion, the TLI and ATG/ATS condition-
ing regimen protected both mice and rats against
GVHD. Protection was dependent on the presence of
host NK T cells and was associated with a Th2 bias of
host and donor T cells in the surviving stable chime-
ras.
Figure 6. Cytokine secretion patterns of donor and host T cells in BALB/c mixed chimeras. Wild-type BALB/c hosts were given TLI, ATS,
C57BL/6 BMT (3  106 BM cells and 0.5  106 PBMC), and observed for at least 100 days as in Figure 5. Spleen cells from 3 surviving hosts
were pooled, stained for TCR, H-2Kb (donor-type) and H-2Kd (host type) surface markers, and analyzed using 3-color ﬂow cytometric
analysis. Gated TCR T cells (enclosed in box in left panel) were analyzed for H-2Kb versus H-2Kd subsets (enclosed in boxes in middle
panel). H-2Kb and H-2Kd–positive cells were sorted, and 0.2  106 cells per well were stimulated in vitro with phorbol myristate acetate and
calcium ionophore. After 48 hours, culture supernatants were assayed for the concentration of IL-4 and IFN- by the ELISA technique (right
panel). Control cultures used sorted splenic TCR T cells from wild-type C57BL/6 (WT B6) or BALB/c (WT BALB/c) untreated mice.
Bars show the mean concentrations of 5 individual cultures and brackets show the standard errors. One of 2 replicate experiments is shown
in which pooled cells from a total of 6 mice were analyzed.
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